Companies › Alpine Immune Sciences
2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 3; Immunology, Genitourinary; next expected readout Jan 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Povetacicept (ALPN-303) Dual CD27/CD70 co-stimulation inhibitor | CD27, CD70 | Phase 3 | Immunoglobulin A Nephropathy | Jan 2028 |
| Povetacicept (ALPN-303) CD27 costimulatory molecule inhibitor | CD27 | Phase 1 | Lupus Nephritis | Mar 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06564142 | Povetacicept (ALPN-303) | Phase 3 | Immunoglobulin A Nephropathy | Genitourinary | Jan 2028 |
| NCT05732402 | Povetacicept (ALPN-303) | Phase 1 | Lupus Nephritis | Immunology | Mar 2028 |
Chongqing Precision Biotech Allogene Therapeutics Xilio Development Pfizer Beijing Biotech OncoVerity Qilu Pharmaceutical Hrain Biotechnology Adicet Therapeutics
Climb Bio RAPT Therapeutics, Inc., a member of the GSK plc group of companies Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) Chengdu Kangnuoxing Biopharma AnaptysBio
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.